View of Design and rationale for a randomized, double-blind, placebo-controlled Phase 2/3 trial of oral arimoclomol in inclusion body myositis

Return to Article Details Design and rationale for a randomized, double-blind, placebo-controlled Phase 2/3 trial of oral arimoclomol in inclusion body myositis Download Download PDF